Fulcrum Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Fulcrum Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.2 times its market value (net cash). Higher than 91% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-139.3×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 86% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / +62%In 3 years sales changed by -100% while total assets changed by +62%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-25.0×Operating cash was negative last year, while some debt falls due within a year.
Lower than 60% of Healthcare companies in United States.
Cash Cushion Ratio
1.2× cashCash, after subtracting all debt, is 1.2 times its market value (net cash).
Higher than 91% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Fulcrum Therapeutics, Inc. made a loss over the last year. Fulcrum Therapeutics, Inc. owes $0.04 for every $1 it owns. Fulcrum Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossFulcrum Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.90The share price is 0.90 times Fulcrum Therapeutics, Inc.'s book value per share, lower than 81% of Healthcare companies in United States.
Market cap
$281 MThe total market value of all of Fulcrum Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 53% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$311 MWhat Fulcrum Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.07Net worth divided by the number of shares. The share price of $3.68 is 0.9 times this, which is the P/B above.
Return on equity (ROE)
-32.4%Fulcrum Therapeutics, Inc. lost 32.4% of its shareholders' money over the last year, higher than 60% of Healthcare companies in United States.
Owes vs Owns
0.04×Fulcrum Therapeutics, Inc. owes $0.04 for every $1 it owns (low), lower than 98% of Healthcare companies in United States.
Dividend yield
NoneFulcrum Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossFulcrum Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashFulcrum Therapeutics, Inc. held $346 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Fulcrum Therapeutics, Inc.: $281 M ÷ $311 M (30 Jun 2026) = 0.9.
What is Fulcrum Therapeutics, Inc.'s return on equity?
Fulcrum Therapeutics, Inc. lost 32.4% of its shareholders' money over the last year, higher than 60% of Healthcare companies in United States.
How much does Fulcrum Therapeutics, Inc. owe compared with what it owns?
Fulcrum Therapeutics, Inc. owes $0.04 for every $1 it owns (low), lower than 98% of Healthcare companies in United States.
Does Fulcrum Therapeutics, Inc. pay a dividend?
No. Fulcrum Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.